Navigation Links
Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
Date:3/26/2013

nations) and negative (e.g., flat affect) symptoms of schizophrenia.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding the potential qualities of OMS824; that it will request orphan drug and Fast Track designations for OMS824; that it will advance OMS824 into a Phase 2 clinical program; that it will submit an NDA and MAA for OMS302 this year; that it will advance its MASP-2 and PDE7 programs into the clinic in the coming months; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
2. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
4. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
5. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
6. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
7. Omeros is Not Aware of Any Justification for Share Price Movement
8. Omeros Corporation Reports Third Quarter 2012 Financial Results
9. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
10. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today announced ... shares of its common stock at a price to ... to Tandem from this offering are expected to be ... other estimated offering expenses payable by Tandem. All of ...
(Date:2/26/2015)... 26, 2015  Today the National Safety Council ... and physical side effects of pain medications ... as Vicodin and Oxycontin, are safer options than over-the-counter ... prescription painkillers than on heroin and cocaine combined," said ... NSC. "Yet, these medications are marketed as the Cadillac ...
(Date:2/26/2015)... , Feb. 26, 2015  Mobility Ventures LLC, ... agreement with Bank of America (NYSE: BAC ... to receive financing of the revolutionary MV-1 - - ... from the ground up to provide safe and comfortable ... can use their loan to purchase a new MV-1 ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... 2012   Polar , the leader in heart rate monitoring ... the "Official Heart Rate Technology Supplier" for U.S. Soccer through ... year packed with major national and international events, including the ... from Polar will be used to help these nine National ...
... Software Systems, Inc. the leading provider of computerized ... is pleased to announce the latest release of ... release, we have included a number of new ... The new release of TMS ...
Cached Medicine Technology:Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 2Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 3Four Rivers Software Systems Launches TMS 2012.5.5 2
(Date:2/28/2015)... Fredericton, NB (PRWEB) February 28, 2015 ... call center software suite for Asterisk, are pleased to ... the highly successful 5.7 and 5.8 versions of Q-Suite, ... as well as a number of new features to ... be Q2 2015. , Q-Suite 5.9 will add features ...
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 For ... conference in person, the Mesothelioma Applied Research Foundation ... place on Tuesday, March 3, starting at 9:30 AM. ... requires no registration. The broadcast can be accessed through ... http://www.curemeso.org/symposium . , The Symposium is a unique ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be ... Materials Show, an annual, premier sustainable building event in ... top manufacturers of the latest building products, services and ... and manufactured by Pioneer Millworks from their Oregon and ... restaurants, hotels, retailers, and corporate offices. Nichibi Global ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Dr. ... Central Coast area residents, recently announced a special offer ... It’s a treatment option for new and established patients ... 2015 with a bright, white smile, Dr. Patel and ... of $299, marked down from the regular price of ...
(Date:2/28/2015)... York, NY (PRWEB) February 28, 2015 ... discuss federal testosterone lawsuits that have been filed by ... for the second week in March, the Firm notes. ... Court’s website, parties involved in the federal litigation will ... address matters related to prescription therapy treatments designed to ...
Breaking Medicine News(10 mins):Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... 16 HHS Secretary Mike,Leavitt today declared a ... and Indiana. The action gives HHS, Centers for ... health care,providers greater flexibility in meeting emergency health ... is devastating to each individual and,to their communities," ...
... Technical Staff, and 7 other HFI usability, experts ... and research topics including, ,Who are ... NEW YORK, June 16 Human Factors International ... its "platinum",sponsorship of the 2008 Usability Professionals, Association ...
... new family of therapeutic agents that interferes with the ... cancer cells. The results of the new study will ... 90th Annual Meeting in San Francisco. , The ... and related compounds are likely to be effective against ...
... CHICAGO Two research studies evaluating dietary changes and ... (IBD) have been launched at Rush University Medical Center. ... study will look at the impact of mind/body medicine ... other will assess how diet impacts patients with Crohn,s ...
... of humans with disease, study says , , MONDAY, June 16 ... lives of dogs with cancer may also be able to ... better quality of life, the therapy,s developers say. , ... 55 dogs with cancer and anemia. It increases muscle strength ...
... 16 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX :,HAE), ... plasma-derived protein products for commercialization,announces that it ... of amended,Series B warrants and broker warrants ... in January 2007., "I sincerely thank ...
Cached Medicine News:Health News:HHS Takes Action to Help Medicare Beneficiaries and Providers in Iowa and Indiana 2Health News:HHS Takes Action to Help Medicare Beneficiaries and Providers in Iowa and Indiana 3Health News:Human Factors International Sponsors Usability Professionals' Association (UPA) 2008 International Conference 2Health News:Human Factors International Sponsors Usability Professionals' Association (UPA) 2008 International Conference 3Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Study underway to find an alternative cure for Crohn's disease and ulcerative colitis 2Health News:Gene Therapy Helps Dogs Stricken With Cancer 2Health News:Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic 2Health News:Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic 3
... from Viasys Neurocare is a full-featured physiologic testing ... size. It contains many of the features of ... at an economical price. , ,The smaller size ... crowded lab environment, the physician's office, a mobile ...
... The Imexlab 3000DX bidirectional vascular testing ... convenience for the physician concerned with ... is designed and made by Nicolet ... vascular diagnostic systems chosen by thousands ...
The CD Horizon M10 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
Scoliosis Devices....
Medicine Products: